RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

(2018) Mark A. Socinski et al.   Journal of Thoracic Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

(2017) Mark G. Kris et al.   JOURNAL OF CLINICAL ONCOLOGY

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer

(2017) Alberto Ballestrero et al.   Journal of Translational Medicine

Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems

(2017) Yi Xiong et al.   MEDICAL ONCOLOGY

Cell signalling pathway regulation by RanBPM: molecular insights and disease implications

(2017) Louisa M. Salemi et al.   Open Biology

On the Dependency of Cellular Protein Levels on mRNA Abundance

(2016) Yansheng Liu et al.   CELL

DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer

(2016) Catherine R. Sears et al.   DNA REPAIR

Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma

(2016) Kozo Kuribayashi et al.   Journal of Cancer Research and Therapeutics

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

(2016) Takehito Shukuya et al.   Journal of Thoracic Oncology

mRNA modifications: Dynamic regulators of gene expression?

(2016) Thomas Philipp Hoernes et al.   RNA Biology

DNA Repair—A Double-Edged Sword in the Genomic Stability of Cancer Cells—The Case of Chronic Myeloid Leukemia

(2015) Elzbieta Pawlowska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins

(2015) Sayo Horibe et al.   LIFE SCIENCES

Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1

(2015) Sebastian Eustermann et al.   MOLECULAR CELL

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

(2015) Raphael Ceccaldi et al.   NATURE

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

(2015) P. A. Konstantinopoulos et al.   Cancer Discovery

Preclinical Murine Models for Lung Cancer: Clinical Trial Applications

(2015) Amelia Kellar et al.   Biomed Research International

Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells

(2014) Lucy Swift et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chemotherapy induced DNA damage response

(2013) Derek Woods et al.   CANCER BIOLOGY & THERAPY

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

(2013) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Insights into the regulation of protein abundance from proteomic and transcriptomic analyses

(2012) Christine Vogel et al.   NATURE REVIEWS GENETICS

RanBPM Is an Inhibitor of ERK Signaling

(2012) Elnaz Atabakhsh et al.   PLoS One

Diverse roles of the scaffolding protein RanBPM

(2011) Bharathi Suresh et al.   DRUG DISCOVERY TODAY

Stability and Function of Mammalian Lethal Giant Larvae-1 Oncoprotein Are Regulated by the Scaffolding Protein RanBPM

(2010) Bharathi Suresh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

RanBPM Has Proapoptotic Activities That Regulate Cell Death Pathways in Response to DNA Damage

(2009) E. Atabakhsh et al.   MOLECULAR CANCER RESEARCH